CG Oncology, Inc. (CGON)
| Market Cap | 6.13B +273.6% |
| Revenue (ttm) | 5.07M +666.0% |
| Net Income | -186.75M |
| EPS | -2.35 |
| Shares Out | 88.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,143,030 |
| Open | 68.90 |
| Previous Close | 69.18 |
| Day's Range | 68.55 - 70.32 |
| 52-Week Range | 21.90 - 73.56 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 77.90 (+11.89%) |
| Earnings Date | May 8, 2026 |
About CGON
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with... [Read more]
Financial Performance
In 2025, CG Oncology's revenue was $4.04 million, an increase of 254.70% compared to the previous year's $1.14 million. Losses were -$161.00 million, 82.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price target is $77.9, which is an increase of 11.89% from the latest price.
News
CG Oncology reports Q1 EPS (71c), consensus (54c)
Reports Q1 revenue $1.08M, consensus $453,030. “We have successfully completed non-clinical and clinical modules for our first BLA submission. The remaining CMC module is progressing as planned, and w...
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
CG Oncology to Present at Upcoming Investor Conferences in May
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, ...
CG Oncology price target raised to $79 from $73 at RBC Capital
RBC Capital raised the firm’s price target on CG Oncology (CGON) to $79 from $73 and keeps an Outperform rating on the shares. One of the most complex catalysts in
JPMorgan ups CG Oncology target, adds ‘Positive Catalyst Watch’
JPMorgan raised the firm’s price target on CG Oncology (CGON) to $91 from $65 and keeps an Overweight rating on the shares. JPMorgan also placed CG on “Positive Catalyst Watch”
CG Oncology price target raised to $84 from $72 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on CG Oncology (CGON) to $84 from $72 and keeps a Buy rating on the shares. Shares have run up 62%
JPMorgan healthcare analysts hold an analyst/industry conference call
Healthcare Analysts discuss Non-muscle invasive bladder cancer (NMIBC) (relevant companies CG Oncology (CGON) and Protara Therapeutics (TARA) on an Analyst/Industry conference call to be held on April...
CG Oncology price target raised to $100 from $80 at H.C. Wainwright
H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on CG Oncology (CGON) to $100 from $80 and keeps a Buy rating on the shares as part of a
CG Oncology price target raised to $90 from $60 at UBS
UBS raised the firm’s price target on CG Oncology (CGON) to $90 from $60 and keeps a Buy rating on the shares. CG Oncology’s Phase 3 PIVOT-006 trial is evaluating
CG Oncology price target raised to $72 from $65 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on CG Oncology (CGON) to $72 from $65 and keeps a Buy rating on the shares. The firm views today’s data
CG Oncology Transcript: TD Cowen 46th Annual Health Care Conference
Credo demonstrates strong efficacy and durability in multiple bladder cancer settings, with a 75.5% CR rate in BOND-003 and promising adjuvant and combination data. Regulatory filings are underway, with commercial launch preparations targeting a concentrated market and leveraging a robust team.
CG Oncology price target raised to $80 from $75 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on CG Oncology (CGON) to $80 from $75 and keeps a Buy rating on the shares. CG Oncology is progressing toward a biologics
CG Oncology reports FY25 EPS ($2.08), consensus (58c)
Reports revenue $4.04M, consensus $515,180. “In the coming months, we look forward to sharing topline data from PIVOT-006, the first randomized registrational trial to evaluate an investigational ther...
CG Oncology sees cash runway into 1H29
Net proceeds of approximately $188.0 million was raised from a total of 3,623,101 shares sold in January 2026 through the Company’s ATM facility, resulting in a cash, cash equivalents, and
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updat...
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating ...
CG Oncology price target raised to $75 from $66 at Truist
Truist raised the firm’s price target on CG Oncology (CGON) to $75 from $66 and keeps a Buy rating on the shares. The firm cites its expectations for the company
CG Oncology price target raised to $73 from $61 at RBC Capital
RBC Capital raised the firm’s price target on CG Oncology (CGON) to $73 from $61 and keeps an Outperform rating on the shares. The firm updated models for several biotech
CG Oncology price target raised to $70 from $55 at Piper Sandler
Piper Sandler analyst Kelsey Goodwin raised the firm’s price target on CG Oncology (CGON) to $70 from $55 and keeps an Overweight rating on the shares. Following a flurry of
CG Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference
The session highlighted strong clinical progress for a novel bladder-sparing immunotherapy, with pivotal trials in both high-risk and intermediate-risk NMIBC nearing key data readouts. The therapy shows best-in-class efficacy, safety, and commercial readiness, with regulatory submissions and market expansion planned through 2027.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: CG Oncology (CGON), 1,146.51% surge in interest Summit Th...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: CG Oncology (CGON), 849.76% surge in interest AIM ImmunoT...
CG Oncology price target raised to $66 from $62 at Truist
Truist raised the firm’s price target on CG Oncology (CGON) to $66 from $62 and keeps a Buy rating on the shares. The firm cites the company’s updated timeline for
CG Oncology price target raised to $82 from $55 at Goldman Sachs
Goldman Sachs raised the firm’s price target on CG Oncology (CGON) to $82 from $55 and keeps a Buy rating on the shares. CG Oncology’s advancement of the pivotal PIVOT-006
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule